NEW YORK (
CHANGE IN RATINGS
initiated at JP Morgan. Initiated with an Overweight rating and $40.50 price target. Introduces 2010 EPS estimates of $4.96.
upgraded at Baird from Neutral to Outperform. $32 price target. Company is seeing better sales and traffic trends.
Clear Channel Outdoor
upgraded at Piper Jaffray. Rating raised to Neutral from Underweight. Price target raised to $12 from $6. 2010 EPS estimates lowered to -$0.11 from -$0.04.
downgraded at UBS from Buy to Neutral. $11 price target. Estimates also lowered, given pricing pressures in the milk market.
( ERTS) upgraded at MKM from Sell to Neutral. Company is turning the business around and seeing better sales from its new titles.
upgraded at BofA/Merrill to Neutral from Underperform on cost savings, large buyback and better flows. Price target maintained at $31.
downgraded at Barclays to Equal Weight from Overweight on valuation. Maintain $14 price target.
upgraded at Deutsche from Hold to Buy. $14 price target. New plans should drive subscriber growth.
rated new Buy at Jefferies. $39 price target. Company should benefit from a resurgence in discretionary spending.
rated new Neutral at UBS. PRI was initiated with a Neutral rating. $27 price target. Company can deliver double-digit earnings growth by 2012, but faces compliance issues.
rated new Buy at Deutsche Bank. $19 price target. Industry trends are improving and organic growth could accelerate.
St Jude Medical
upgraded at Piper Jaffray to Overweight from Neutral. Maintains $44 price target and 2010 EPS estimates of $2.84.
initiated at Barclays with an Overweight rating and $23 price target. Sales are recovering broadly and the TLB story is just getting started.
estimates increased at Morgan Stanley through 2011. Protein market is improving and the company is seeing better operating efficiency. Equal-weight rating.
downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Price target lowered to $21 from $23.
STOCK COMMENTS / EPS CHANGES
estimates, target raised at Kaufman. Shares of AAPL now seen reaching $320. Estimates also increased, given higher expected Mac and iPad sales. Buy rating.
More on Apple
Five Products Apple Should Make
estimates raised at UBS through 2011. Company is seeing an improvement in production. Buy rating and $40 price target.
numbers boosted at Credit Suisse. BMR price target lifted by a dollar to $17 on solid 1Q10 earnings. Estimates raised through 2012. Maintain Neutral rating.
target upped at Morgan Stanley to $42. Company can deliver organic growth and is buying back stock. Equal-weight rating and $42 price target.
estimates boosted at Goldman through 2012. Company is seeing higher subscriber growth. Sell rating and $18 price target.
estimates reduced at UBS through 2011. Company reported a lower backlog this quarter. Buy rating and $60 price target.
target, estimates tweaked at Barclays. FLR price target lowered a dollar to $58 on mixed 1Q10 results. 2010 and 2011 EPS estimates trimmed to $2.85 and $3.20, respectively.
estimates, target upped at UBS. FMC estimates were boosted through 2011. Soda Ash market is gaining momentum. Buy rating and new $73 price target.
estimates increased at UBS through 2011. Company is realizing higher prices and spending less on CapEx. Buy rating and $16 price target.
target, estimates higher at Citi. LM price target increased to $33.50 from $29.50 to reflect cost-reductions and share repurchases. Estimates lifted through 2012. Maintain Hold rating.
estimates increased at FBR through 2012. Buybacks should offset restructuring costs. Market Perform rating and $33 price target.
price target higher at Credit Suisse by a dollar to $21 on strong 3Q10 results. Estimates increased through 2012. Maintain Neutral rating.
estimate raised at Barclays. MRO 2010 EPS estimates jumped to $3.10, 2011 held at $4.30. Oil discovered in the Flying Dutchman area. Maintain Equal Weight rating and $34 price target.
numbers boosted at FBR. Shares of NUAN now seen reaching $21. Estimates also upped, as the company is posting double-digit organic growth. Outperform rating.
numbers lowered at Goldman. Shares of PCLN now seen reaching $260. Estimates also cut, given the weaker Euro and travel delays from the volcanic ash. Neutral rating.
estimates lowered at Morgan Stanley through 2012. Company has significant exposure to Europe. Overweight rating and $57 price target.
estimates reduced at Morgan Stanley through 2011. Rate hikes will likely come later than expected. Overweight rating and $21 price target.
target raised at Morgan Stanley to $52. Company is seeing better rating and should benefit from an advertising recovery. Equal-weight rating.
estimates, target reduced at Goldman. TIF estimates were cut through 2012. Company has heavy exposure to Asia and Europe. Neutral rating and new $52 price target.
estimates lowered at Goldman through 2012. Company is being hurt by the weaker Pound and Euro. Buy rating.
estimates cut at Goldman through 2012. Company seeing impact from the weaker Pound and Yen. Buy rating.
estimates boosted at UBS through 2011. Company has a strong pipeline on both sides of the business. Neutral rating and $43 price target.
This article was written by a staff member of TheStreet.com.